- Conditions
- Ulcerative Colitis
- Interventions
- Duvakitug, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 120
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 103 more
Location Directory
Clinical trials in San Antonio, Texas
This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3151
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 133–144 of 3,151 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Obesity or Overweight
- Interventions
- Maridebart Cafraglutide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 45 more
- Conditions
- COVID-19, Sars-CoV-2 Infection
- Interventions
- NVX-CoV2705, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 6,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 99
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 989
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
- Interventions
- VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Coral Springs, Florida • Jacksonville, Florida + 21 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor, Placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 69
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Coronado, California + 51 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Sotorasib, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 30
- States / cities
- Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 25 more
- Conditions
- Kidney Disease
- Interventions
- Mezagitamab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 37 more
- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 57
- States / cities
- Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more
- Conditions
- Acute Kidney Injury
- Interventions
- Selective Cytopheretic Device, Standard of Care
- Device · Other
- Lead sponsor
- SeaStar Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
- Conditions
- Symptomatic Venous Thromboembolism (VTE)
- Interventions
- REGN7508, Acetylsalicylic Acid (ASA), Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 38
- States / cities
- La Mesa, California • Rancho Mirage, California • Riverside, California + 30 more
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
- Interventions
- Axitinib, Nivolumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 266
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 168 more